Condition: Breast Cancer · Sponsor: Amsterdam UMC, location VUmc
In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.
This description comes directly from the study's public registry record.
Janneke van Roij, MD · +31 6 11094077 · j.s.vanroij@amsterdamumc.nl
Desirée van den Bongard, MD, PhD · h.j.vandenbongard@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| GenesisCare | Sydney, Australia | Not Yet Recruiting |
| Flevoziekenhuis | Almere Stad, Netherlands | Recruiting |
| Ziekenhuis Amstelland | Amstelveen, Netherlands | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Recruiting |
| Canisius Wilhelmina Ziekenhuis | Nijmegen, Netherlands | Recruiting |
| Radboud UMC | Nijmegen, Netherlands | Recruiting |
| Zaans Medisch Centrum | Zaandam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05350722